EP0211072A1 - Komprimat - Google Patents
KomprimatInfo
- Publication number
- EP0211072A1 EP0211072A1 EP86901366A EP86901366A EP0211072A1 EP 0211072 A1 EP0211072 A1 EP 0211072A1 EP 86901366 A EP86901366 A EP 86901366A EP 86901366 A EP86901366 A EP 86901366A EP 0211072 A1 EP0211072 A1 EP 0211072A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- compressed
- tablet
- ophthalmologically acceptable
- polymer
- carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
Definitions
- the invention relates to a new compressed product for local ophthalmic use.
- Isters or other sheet-like or lamellar shaped bodies which are inserted into the lower conjunctival sac and which delay the release of active ingredient can only be produced with considerable outlay in terms of process technology and are often unsuitable for long-term use due to a lack of compatibility.
- Even new therapeutic systems propagated in recent years - eg Ocuserr- 'for ophthalmology - have not been able to solve the existing problems, the manufacture of such chamber-like molded articles consisting of plastics is very complex, and the question must also be asked whether an extension of the effect over a period of seven days makes any sense.
- An inadequate chemical stability often speaks against an excessively long residence time of active substances in the tear fluid, for example in the case of pilocarpine.
- the object of the invention is to provide pharmaceutical preparations for local ophthalmic use which can be obtained in a relatively simple and inexpensive manner and which guarantee an effect lasting from about 12 to 24 hours.
- compressed tablets can be produced with the aid of tablet machines, which are largely adapted to the anatomical conditions of the eye when water-insoluble ophthalmologically acceptable carriers are used.
- the invention relates to a compressed product for local ophthalmic use of 8 to 14 mm in length, 3 to 14 mm in width and 0.05 to 1 mm in height, comprising at least one water-insoluble ophthalmologically acceptable carrier and at least one ophthalmologically acceptable active ingredient.
- Suitable carrier substances are, in particular, polymer substances which are indifferent to water and tear fluid, for example the polymethyl methacrylic acid esters (PMMA) which are also used for the production of contact lenses, and other polymethacrylates and the corresponding polyacrylates.
- PMMA polymethyl methacrylic acid esters
- polyacrylic acid derivatives with acidic, e.g. Carboxyl, or basic, e.g. Ammonium groups are used, which may also be in the form of their salts.
- the compressed products according to the invention are thin slices of 8 to 14, preferably 10 to 12 mm in length, 3 to 14, preferably 4 to 8 mm in width and 0.05 to 1, preferably 0.1 to 0.5 mm web height.
- You can use any, for example angular, for example square, pentagonal or hexagonal, or in rounded, for example circular, oval or - preferably - kidney-shaped form. They can be flat or curved, in particular adapted to the shape of the eye; they can preferably have curvature radii of 11 to 14 mm, expediently 12 to 13 mm.
- aqueous dispersions which have an average molecular weight of the polymer substance of 0.5 to 1.5 million, preferably of about 800,000, and a
- Adhesion of the molding compound to the punches can generally be added by adding approx. 2 to 20. ⁇ , preferably 8 to 12 ?. Water can be avoided. It is also possible to improve the tabletting ability by adding about 0.5 to 5, preferably 0.5 to 2?? Of highly disperse silica - for example Aerosil ⁇ ' 200 - without adversely affecting the compressed product or the active ingredient enter.
- Suitable basic components which are also suitable as additives, are Eudragit ⁇ RS and Eudragit ⁇ L. If these substances are not used in the form of aqueous dispersions, e.g. the anionic compound (Eudragit ⁇ - L) after adjustment to a pH of> 7 by drying, e.g. Spray drying, convert into a powder product. Not only aqueous dispersions or aqueous solutions, but also solutions in organic solvents can be subjected to spray drying. It is advisable, for example, to use chloroform-methanol when incorporating Eudragit® RS as a solvent, preferably in a volume ratio of 7: 3.
- the compressions according to the invention can in particular contain active substances from the following groups: Antibacterial agents, for example antibiotics such as chloramphenico gentamycin, neomycin; Sulfonamides such as sulfisomidine, sulfadicram sulfathiazole; quaternary salts such as benzalkonium chloride, cetylpyridinium chloride; Antihistamines such as tetryzolin, antazolin; Antiphlogistics such as hydrocortisone acetate, prednisolone acetate, dexamethasone and its ester, betamethasone and its ester; Berberine chloride; Miotics such as pilocarpine, physostigmine; ⁇ -receptor blockers such as propranolol, timolol or bisoprolol; Mydriatics such as atropine, scopolamine.
- Antibacterial agents for example antibiotics such as chloram
- the active substance (s) can be incorporated into the carrier (s) either by mixing or after drying a solution of the carrier in which the active substance is dissolved or suspended.
- the starting material for tableting can also be obtained by spray drying the carrier and active ingredient together.
- plasticizers such as triacetin, citric acid or sebacic acid esters etc. can be included. Incorporation can be carried out by immersing the compressed products in a solution of the plasticizer in a volatile organic solvent such as ethanol and then drying them.
- kidney-shaped compresses of 10 mg total weight - 10 mm length, 3 mm width, 0.15 mm web height - which have a total duration of action of about 12 to 20 hours are obtained with the aid of a conventional tablet machine .
- compositions are available analogously:
- Example 4 Dexamethasone 0.1? _ Finely divided silica 1
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Ophthalmology & Optometry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19853502962 DE3502962A1 (de) | 1985-01-30 | 1985-01-30 | Komprimat |
DE3502962 | 1985-01-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0211072A1 true EP0211072A1 (de) | 1987-02-25 |
Family
ID=6261081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP86901366A Withdrawn EP0211072A1 (de) | 1985-01-30 | 1986-01-21 | Komprimat |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0211072A1 (xx) |
JP (1) | JPS62501564A (xx) |
AU (1) | AU5516786A (xx) |
DE (1) | DE3502962A1 (xx) |
ES (1) | ES551375A1 (xx) |
HU (1) | HUT42937A (xx) |
IE (1) | IE860259L (xx) |
WO (1) | WO1986004502A1 (xx) |
ZA (1) | ZA86701B (xx) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6713527B2 (en) | 1997-02-07 | 2004-03-30 | Queen's University At Kingston | Anaesthetic bone cement |
US6355705B1 (en) | 1997-02-07 | 2002-03-12 | Queen's University At Kingston | Anaesthetic bone cement |
MX2019003912A (es) * | 2016-10-04 | 2019-12-09 | Cellix Bio Private Ltd | Composiciones y métodos para el tratamiento de xerostomia (sequedad bucal). |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE50901B1 (en) * | 1980-03-04 | 1986-08-06 | Merck & Co Inc | Ophthalmic compositions of carbonic anhydrase inhibitors for topical application in the treatment of elevated intraocular pressure |
-
1985
- 1985-01-30 DE DE19853502962 patent/DE3502962A1/de not_active Withdrawn
-
1986
- 1986-01-21 JP JP61501209A patent/JPS62501564A/ja active Pending
- 1986-01-21 WO PCT/EP1986/000019 patent/WO1986004502A1/de not_active Application Discontinuation
- 1986-01-21 EP EP86901366A patent/EP0211072A1/de not_active Withdrawn
- 1986-01-21 HU HU861490A patent/HUT42937A/hu unknown
- 1986-01-29 IE IE860259A patent/IE860259L/xx unknown
- 1986-01-29 ES ES551375A patent/ES551375A1/es not_active Expired
- 1986-01-30 ZA ZA86701A patent/ZA86701B/xx unknown
- 1986-02-21 AU AU55167/86A patent/AU5516786A/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO8604502A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO1986004502A1 (en) | 1986-08-14 |
IE860259L (en) | 1986-07-30 |
ES551375A1 (es) | 1987-11-16 |
ZA86701B (en) | 1986-09-24 |
JPS62501564A (ja) | 1987-06-25 |
AU5516786A (en) | 1986-08-26 |
HUT42937A (en) | 1987-09-28 |
DE3502962A1 (de) | 1986-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69124115T2 (de) | Methode zur herstellung von systemen mit kontrollierter freisetzung nach einer reaktion nullter ordnung | |
DE69434640T2 (de) | Heterodisperse Hydrogelsysteme zur verzögerten Freisetzung unlöslicher Arzneistoffe | |
DE60200416T2 (de) | Kombination von Carbidopa und Levodopa mit verzögerter Wirkstoffabgabe | |
DE69828993T2 (de) | Kontrollierte abgabe von pharmazeutika in der vorderen augenkammer | |
EP2253665B1 (de) | Gefriergetrocknete Zusammensetzung | |
DE69231415T2 (de) | Stabilisiertes Substrat für kontrollierte Freigabe mit von einer wässerigen Dispersion eines hydrophobischen Polymers abgeleitete Beschichtung | |
DE60112772T2 (de) | Suppositorien die im unteren rectum zurückgehalten werden | |
EP3199147B1 (de) | Gefriergetrocknete wirkstoffzusammensetzung | |
CH666415A5 (de) | System zur kontrollierten abgabe eines darin enthaltenen biologisch aktiven mittels aus einer polymer-matrix. | |
DE69713367T2 (de) | Verfahren zur herstellung einer pharmazeutischen zusammensetzung mit veränderter wirkstoffsfreisetzung, enthaltend eine matrix | |
DE2721603C3 (de) | Beschichtete Körnchen aus Alkalimetallsalzen der Polyacrylsäure und Verfahren zu ihrer Herstellung | |
DE3721163A1 (de) | Traegermaterial fuer augenarzneimittel | |
DE69227259T2 (de) | Film zur lokalen arzneistoffabgabe für periodontale behandlung | |
DE2636559C2 (de) | Stabile Zubereitung zur gleichmäßigen Freigabe einer pharmazeutischen Verbindung | |
DE4120760A1 (de) | Traegersysteme fuer arzneimittel | |
DE1467781A1 (de) | Verfahren zur Herstellung von Dragees mit verlaengerter Wirkstofffreigabe | |
DE69108007T2 (de) | Verfahren zur herstellung einer einen wärme-, licht- und feuchtigkeit empfindlichen wirkstoff mit einer monoklinisch kristallinen struktur enthaltenden tabletten oder dragee zusammensetzung. | |
DE1088192B (de) | Verfahren zur Herstellung von tablettierbaren oder direkt verwendbaren Arzneimittelgranulaten mit einstellbaren Freigabeeigenschaften | |
CH640737A5 (de) | Mittel zur augenbehandlung. | |
EP0108882B1 (de) | Presslinge mit retardierter Wirkstofffreisetzung und Verfahren zu deren Herstellung | |
EP0211072A1 (de) | Komprimat | |
EP1275376B1 (de) | Zweiphasige, tropfbare Hydrogele zur Anwendung am Auge | |
EP2886131B1 (de) | Transparentes Gel | |
DE69007010T2 (de) | Nichtfestes Augenarzneimittel und Verfahren zur Herstellung dieses Arzneimittels. | |
WO1990000391A1 (de) | Arzneimittel-depotform auf alginatbasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19861213 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LI NL SE |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: NUERNBERG, EBERHARD Inventor name: BAUMANN, CHRISTEL |
|
17Q | First examination report despatched |
Effective date: 19880830 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19880802 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 728B |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: BAUMANN, CHRISTEL Inventor name: NUERNBERG, EBERHARD |